Daily ReportSep 19, 2026
Sepsis, September 19 edition
We read 7 papers and selected 3.
Summary
The highest-impact studies addressed adjunctive vitamin C therapy, α7nAChR-mediated neuroprotection in sepsis-associated encephalopathy, and the thromboinflammatory mechanisms of symmetrical peripheral gangrene. The vitamin C meta-analysis provides the strongest clinical evidence but emphasizes that mortality benefit was not confirmed in low-risk-of-bias multicenter trials, while the mechanistic and review studies identify biologically important targets and mechanisms requiring prospective validation.
Research Themes
- Adjunctive treatment strategies in sepsis
- Neuroinflammation and cognitive dysfunction in sepsis-associated encephalopathy
- Thromboinflammatory microvascular injury and peripheral ischemia in shock
Selected Articles
1. α7nAChR alleviates cognitive impairment by promoting autophagy in astrocytes via CaMKK2/AMPK/mTOR pathway in sepsis-associated encephalopathy.
This translational study linked reduced serum α7nAChR levels with sepsis-associated encephalopathy and found moderate predictive performance for SAE risk, with an AUC of 0.79. In a cecal ligation and puncture rat model, α7nAChR activation improved behavioral and neuronal structural outcomes, reduced astrocyte activation and inflammatory cytokines, and promoted autophagy through the CaMKK2/AMPK/mTOR pathway.
Impact: The study provides a mechanistic bridge between a cholinergic receptor, astrocyte autophagy, neuroinflammation, and cognitive dysfunction in sepsis. It also proposes α7nAChR as a candidate biomarker and therapeutic target for sepsis-associated encephalopathy.
Clinical Implications: Serum α7nAChR may warrant evaluation as a biomarker for identifying patients at risk of sepsis-associated encephalopathy. Pharmacologic modulation of α7nAChR is a hypothesis-generating strategy, but clinical translation requires validation in human cohorts and safety studies.
Key Findings
- Serum α7nAChR levels were lower in patients with sepsis-associated encephalopathy than in healthy controls and patients with sepsis without reported encephalopathy, with an AUC of 0.79 for SAE prediction.
- α7nAChR activation improved neurobehavioral scores, increased Nissl bodies and synapses, and improved dendritic spine morphology in septic rats.
- α7nAChR activation reduced astrocyte activation and inflammatory cytokine release while promoting autophagy through the CaMKK2/AMPK/mTOR pathway.
Methodological Strengths
- The study combined a human biomarker analysis with pharmacologic activation and inhibition experiments in a cecal ligation and puncture animal model.
- Neurocognitive and neuronal injury assessments used complementary behavioral, histologic, ultrastructural, and molecular methods.
Limitations
- The human component is observational and the reported abstract does not establish whether reduced α7nAChR levels are causal, prognostic, or influenced by illness severity.
- The principal mechanistic evidence derives from a rat model and pharmacologic agents, so receptor-specific effects and clinical safety remain to be confirmed in humans.
Future Directions: Prospective multicenter studies should validate serum α7nAChR thresholds and temporal changes in relation to encephalopathy. Selective α7nAChR modulators should then be evaluated in well-characterized preclinical models and early-phase clinical trials, with attention to neurobehavioral outcomes and systemic cholinergic adverse effects.
BACKGROUND: Sepsis-associated encephalopathy (SAE) is a syndrome of cerebral dysfunction secondary to sepsis. Although the α7 nicotinic acetylcholine receptor (α7nAChR) plays a pivotal role in the SAE, the specific mechanisms by which it mediates neuroinflammatory responses and contributes to pathological injury in SAE remain unclear. METHODS: The serum α7nAChR level was measured in all included patients. The ROC curve was used to analyze the α7nAChR level for predicting the risk of SAE. The sepsis rat model was constructed by cecal ligation puncture (CLP). The α7nAChR was activated and inhibited by PNU282987 and Methyllycaconitine (MLA) respectively.
2. Intravenous vitamin C as micronutrient therapy in patients with sepsis or septic shock: an updated systematic review and meta-analysis of randomized controlled trials.
This updated systematic review and meta-analysis included 14 randomized controlled trials with 1,958 patients and found an association between intravenous vitamin C and lower 28-day mortality (RR 0.70, 95% CI 0.53-0.93). However, the mortality signal was not confirmed in low-risk-of-bias multicenter trials and was primarily driven by single-center studies; vitamin C appeared safe, but the findings remain exploratory.
Impact: The study synthesizes the most clinically relevant randomized evidence on a widely considered adjunctive therapy for sepsis. Its explicit recognition that the apparent benefit was not reproduced in rigorous multicenter trials helps prevent premature adoption and defines the need for definitive trials.
Clinical Implications: Intravenous vitamin C should not be considered established mortality-reducing standard therapy for sepsis or septic shock on the basis of this meta-analysis alone. It may be considered investigational or protocol-based in selected settings, while clinicians should await high-quality multicenter randomized evidence.
Key Findings
- Fourteen randomized controlled trials involving 1,958 patients were included.
- Intravenous vitamin C was associated with lower 28-day mortality overall, with a relative risk of 0.70 and a 95% confidence interval of 0.53 to 0.93.
- The mortality benefit was not confirmed in low-risk-of-bias multicenter trials and was mainly driven by single-center studies; intravenous vitamin C appeared safe.
Methodological Strengths
- The analysis focused on randomized controlled trials and evaluated mortality, organ dysfunction, vasopressor use, length of stay, and adverse events.
- The authors explicitly examined risk of bias and interpreted the discrepancy between overall findings and low-risk-of-bias multicenter trials.
Limitations
- The apparent mortality benefit was primarily driven by single-center studies, indicating possible heterogeneity, bias, or limited generalizability.
- Subgroup analyses were exploratory and used data-driven thresholds, so the findings cannot establish an optimal dose, timing, or target population.
Future Directions: Large, preregistered, multicenter randomized controlled trials should use standardized vitamin C dosing and timing, prespecified subgroups, clinically meaningful mortality outcomes, and rigorous monitoring for potential adverse effects. Individual-patient-data meta-analysis may help identify biologically or clinically responsive phenotypes.
OBJECTIVE: The adjunctive therapeutic value of vitamin C in sepsis or septic shock patients remains controversial. This study aimed to evaluate the therapeutic efficacy and safety of intravenous administration of vitamin C in sepsis or septic shock patients through meta-analysis. METHODS: Relevant literature was searched in PubMed, Embase, and Scopus databases and other related databases. The primary outcome was 28-day mortality. Secondary outcomes included duration and total dose of vasopressors, change in sequential organ failure assessment (SOFA) scores from baseline to the earliest reported time point between 72 and 96 h (ΔSOFA), hospital length of stay, intensive care unit length of stay, urine output in the 24-h, and incidence of adverse events. RESULTS: Fourteen randomized controlled trials enrolling 1,958 patients were eligible for assessment.
3. Ischemic Limb Necrosis and Symmetrical Peripheral Gangrene During Vasopressor Support in Severe Shock States: Thromboinflammatory Microvascular Injury as the Pathogenic Mechanism.
This review reframes ischemic limb necrosis and symmetrical peripheral gangrene during vasopressor support as manifestations of thromboinflammatory microvascular injury rather than consequences of vasopressor therapy alone. It integrates endothelial injury, glycocalyx disruption, disseminated intravascular coagulation, impaired fibrinolysis, shock liver, depletion of natural anticoagulants, and distal microthrombosis into a clinically coherent mechanism.
Impact: The paper challenges a common clinical attribution that high-dose vasopressors directly cause peripheral gangrene and emphasizes the underlying coagulopathy and shock severity. This distinction may influence bedside evaluation, prognostic assessment, and the design of prevention or treatment studies for limb ischemia in septic shock.
Clinical Implications: When distal ischemia develops during vasopressor therapy, clinicians should assess for disseminated intravascular coagulation, thrombocytopenia, markedly elevated D-dimer, hepatic dysfunction, shock liver, and multiorgan failure rather than attributing the finding to vasopressors alone. Management should prioritize rapid correction of shock and evaluation of thromboinflammatory coagulopathy; the review does not establish a specific antithrombotic treatment.
Key Findings
- Symmetrical peripheral gangrene in severe shock is characterized by distal microthrombosis associated with disseminated intravascular coagulation and thromboinflammatory endothelial injury.
- Endothelial injury, glycocalyx disruption, impaired fibrinolysis, shock liver, and depletion of antithrombin, protein C, and protein S can impair tissue perfusion independently of vasopressor therapy.
- Most patients receiving prolonged or high-dose vasopressors do not develop limb necrosis in the absence of severe coagulopathy, disseminated intravascular coagulation, or shock liver.
Methodological Strengths
- The review integrates coagulation biology, endothelial pathophysiology, hepatic dysfunction, and the clinical phenotype of peripheral gangrene.
- It explicitly addresses confounding in the literature on vasopressor-associated ischemia and distinguishes association from causation.
Limitations
- This is a narrative review and does not provide a pooled effect estimate or prospective validation of the proposed mechanistic framework.
- The relative contributions of vasopressor dose, shock severity, disseminated intravascular coagulation, and patient-specific vascular factors remain difficult to quantify.
Future Directions: Prospective intensive care cohorts should serially measure coagulation, endothelial, hepatic, and microcirculatory biomarkers before and after limb ischemia develops. Mechanism-based trials should evaluate whether early recognition and targeted management of disseminated intravascular coagulation or endothelial dysfunction can reduce tissue loss without increasing bleeding.
Ischemic limb necrosis and resulting symmetrical peripheral gangrene (SPG) are devastating complications of severe shock states, particularly septic shock, and are associated with major morbidity, limb loss, and mortality. These complications usually occur in patients requiring vasopressor support for cardiovascular resuscitation during profound circulatory collapse. In this setting, however, thromboinflammatory microvascular injury represents the principal mechanism underlying ischemic tissue injury. Life-threatening shock is characterized by endothelial injury, glycocalyx disruption, disseminated intravascular coagulation (DIC), impaired fibrinolysis, and ischemic hepatic injury ("shock liver") with endogenous natural anticoagulant factor depletion (antithrombin, protein C, protein S) that promotes diffuse thromboinflammatory microvascular thrombosis and impaired tissue perfusion independent of vasopressor therapy.